P-169 Feasibility of gemcitabine plus cisplatin as neo-adjuvant in cholangiocarcinoma patients prior to liver transplantation

The cholangiocarcinoma management is continually reviewed in the current evidence basis order to develop practice guidelines and consensus statements. However, standardized treatment are still unclear for patients who listed liver transplantation. We aimed validate evaluate potential efficacy of chemotherapy combination Gemcitabine Cisplatin as a neo-adjuvant prior In this prospective case series, with locally advanced, unresectable, hilar, or intrahepatic no extrahepatic disease vascular involvement were treated radiation involved before being transplantation at single cancer center according an open-labeled, center-approved clinical protocol. Patients if minimum six months scans response stability was confirmed. primary endpoints overall survival recurrence-free after This report initial series under ongoing protocol, censored on March 17, 2022,. Between January 19, 2017, 2022, out 701 transplant recipients, only 10 (8 males 2 females) median age 62.71 [interquartile range (IQR): 60.02-71.87] confirmed diagnosis either hilar cholangiocarcinoma. All whom had undergone Median days given 180.5 (IRQ: 120-250). Nine (90%) reported recurrence metastasis, 1 patient metastasis (10%); 612 patient. received while awaiting follow-up 850.5 (IQR: 813-967). Overall 100% (95% CI 100-100) year years, respectively. third year, 75% CI: 12.8%-9%). 6.1One died 885 days. No adverse events including recurrent. Our finding demonstrated that have shown excellent outcome live